Teleflex Launches Global Pivotal Trial for Resorbable Magnesium Scaffold
Event summary
- Teleflex begins enrollment in the BIOMAG-III Study (NCT07258290), a global pivotal trial for its Freesolve Resorbable Magnesium Scaffold.
- The randomized controlled trial will enroll 1,859 patients across up to 120 sites worldwide, comparing Freesolve RMS to Xience DES on Target Lesion Failure (TLF) rates at 12 months.
- Enrollment for the BIOMAG-II Study completed ahead of schedule with 1,861 patients across 20 countries.
- Positive long-term data from the BIOMAG-I First-In-Human Study showed a 3.5% TLF rate at four years.
The big picture
Teleflex's initiation of the BIOMAG-III Study marks a significant step in advancing resorbable scaffold technology, potentially offering an alternative to permanent metallic implants. The study's global scale and rigorous design underscore Teleflex's commitment to transforming coronary intervention treatments. Success could position Freesolve RMS as a competitive option in the interventional cardiology market.
What we're watching
- Regulatory Pathway
- Whether the BIOMAG-III Study will generate sufficient pivotal evidence to support future regulatory approvals for Freesolve RMS.
- Clinical Outcomes
- The long-term safety and efficacy of Freesolve RMS compared to traditional drug-eluting stents, particularly in reducing long-term events associated with permanent metallic implants.
- Market Adoption
- The pace at which resorbable scaffold technology could reshape the coronary intervention landscape if proven successful.